Change(s) applied to document, /T.M.F./ 3/11/2011

Please replace Table 1 on page 7 with the following table:

--TABLE 1: Medium Formulation, Versions PDX-1 and PDX-2.

Ingredient	PDX-1 (g/L)	PDX-2 (g/L)
Tryptone	17.0	17.0
Peptone	3.0	3.0
Sodium Chloride	5.0	5.0
Dibasic Potassium Phosphate (anhydrous)	6.0	6.0
Yeast extract	6.0	6.0
Cycloheximide ~~**Cyclohexamide**~~	0.05	0.05
Acriflavin	0.01	-
Naladixic acid	0.04	0.04
Esculin	1.0	1.0

--

Please replace Table 2 starting on page 7, line 15 and ending on page 8, line 6 with the following table:

--TABLE 2: Supplements.

Supplement name	PDX-1	PDX-2
Ceftazidime ~~**Ceftazimide**~~	0.04 g/L	0.04 g/L
Phosphomycin	0.04 g/L	0.04 g/L
Polymyxin E	0.01 g/L	0.01 g/L
Ferric Ammonium Citrate	0.5 g/L	0.5 g/L
Lithium Chloride*	5.0 g/L	5.0 g/L
Nitrofurantoin**	-	0.006 g/L

*Lithium chloride is exothermic when dissolved in water. Appropriate care must be taken when adding it to the medium.

**Nitrofurantoin is insoluble in water. A 10 mg/mL stock solution was made in sterile DMSO. The nitrofurantoin/DMSO stock solution was then added to the rest of the medium (600 microliters of stock solution/L medium yields 0.006 g/L nitrofurantoin in the final medium). Solid-medium plates were made from the liquid

IN THE SPECIFICATION

Change(s) applied to document, /T.M.F/ 3/11/2011

Please replace the paragraph on page 4, line 21 ~~lines 8-26~~ in the specification with the following paragraph:

--In a preferred embodiment (see PDX-1 in Table 1), the medium comprises tryptone, in a concentration ranging from about 15 to about 25 g/L, with a preferred concentration of about 16 to about 18 g/L, with a further preferred concentration of about 17 g/L; peptone, in a concentration ranging from about 1 to about 5 g/L, with a preferred concentration of about 2 to about 4 g/L, with a further preferred concentration of about 3 g/L; sodium chloride, in a concentration ranging from about 1 to about 10 g/L, with a preferred concentration of about 2.5 to about 7.5 g/L, with a further preferred concentration of about 5 g/L; anhydrous dibasic potassium phosphate, in a concentration ranging from about 1 to about 10 g/L, with a preferred concentration of about 2.5 to about 7.5 g/L, with a further preferred concentration of about 5 g/L; yeast extract, in a concentration ranging from about 1 to about 10 g/L, with a preferred concentration of about 2.5 to about 7.5 g/L, with a further preferred concentration of about 6 g/L; **cycloheximide** ~~**cycloheximide**~~, in a concentration ranging from about 0.01 to 0.1 g/L, with a preferred concentration of about 0.025 to about 0.075 g/L, with a further preferred concentration of about 0.05 g/L; acriflavin, in a concentration ranging from no more than about 0.01; naladixic acid, in a concentration ranging from about 0.01 to about 0.1 g/L, with a preferred concentration of about 0.025 to about 0.075 g/L, with a further preferred concentration of about 0.04 g/L; and esculin, in a concentration ranging from about 0.5 to 5 g/L, with a preferred concentration of about 0.75 to about 2 g/L, with a further preferred concentration of about 1 g/L.—

Please replace the paragraph on page ~~4~~ 5, lines ~~27-31~~ 10-14 in the specification with the following paragraph:

-- In an especially preferred embodiment (see PDX-2 in Table 1), the selective medium of the present invention comprises tryptone, peptone, sodium chloride, anhydrous dibasic potassium